Concise review of radiosurgery for contemporary management of pilocytic astrocytomas in children and adults

Omer Sager, Ferrat Dincoglan, Selcuk Demiral, Bora Uysal, Hakan Gamsiz, Esra Gumustepe, Fatih Ozcan, Onurhan Colak, Ahmet Tarik Gursoy, Cemal Ugur Dursun, Ahmet Oguz Tugcu, Galip Dogukan Dogru, Rukiyye Arslan, Yelda Elcim, Esin Gundem, Bahar Dirican, Murat Beyzadeoglu

Specialty type: Oncology
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Hata M, Japan
Received: September 30, 2021
Peer-review started: September 30, 2021
First decision: March 7, 2022
Revised: March 9, 2022
Accepted: April 21, 2022
Article in press: April 21, 2022
Published online: May 20, 2022

Abstract
Pilocytic astrocytoma (PA) may be seen in both adults and children as a distinct histologic and biologic subset of low-grade glioma. Surgery is the principal treatment for the management of PAs; however, selected patients may benefit from irradiation particularly in the setting of inoperability, incomplete resection, or recurrent disease. While conventionally fractionated radiation therapy has been traditionally utilized for radiotherapeutic management, stereotactic irradiation strategies have been introduced more recently to improve the toxicity profile of radiation delivery without compromising tumor control. PAs may be suitable for radiosurgical management due to their typical appearance as well circumscribed lesions. Focused and precise targeting of these well-defined lesions under stereotactic immobilization and image guidance may offer great potential for achieving an improved therapeutic ratio by virtue of radiosurgical techniques. Given the high conformality along with steep dose gradients around the target volume allowing for reduced normal tissue exposure, radiosurgery may be considered a viable modality of radiotherapeutic management. Another advantage of radiosurgery may be the completion of therapy in a usually shorter overall treatment time, which may be particularly well suited for children with requirement of anesthesia during irradiation. Several studies have addressed the utility of radiosurgery particularly as an adjuvant or salvage treatment modality for PA. Nevertheless, despite the growing body of evidence supporting the use of radiosurgery, there is need for a high level of evidence to dictate treatment decisions and establish its optimal role in the management of PA. Herein, we provide a concise review of radiosurgery for PA in light of the literature.
Key Words: Pilocytic astrocytoma; Radiosurgery; Stereotactic irradiation; Low-grade glioma; Radiation oncology; Children

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Radiosurgery for pilocytic astrocytomas may be utilized as part of initial management, as adjuvant therapy, or for the salvage of recurrences. Radiosurgery offers a convenient procedure by a condensed treatment schedule with rapid recovery. An improved toxicity profile may be achieved through optimal normal tissue sparing. Accurate setup verification under stereotactic immobilization and image guidance may be achieved, and the procedure is convenient with regards to staff and facility workload.

Citation: Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, Gumustepe E, Ozcan F, Colak O, Gursoy AT, Dursun CU, Tugcu AO, Dogru GD, Arslan R, Elcim Y, Gundem E, Dirican B, Beyzadeoglu M. Concise review of radiosurgery for contemporary management of pilocytic astrocytomas in children and adults. World J Exp Med 2022; 12(3): 36-43
URL: https://www.wjgnet.com/2220-315x/full/v12/i3/36.htm
DOI: https://dx.doi.org/10.5493/wjem.v12.i3.36

INTRODUCTION

Gliomas are neuroepithelial tumors arising from supporting glial cells of the central nervous system (CNS). Low-grade glioma (LGG) may be seen in both adults and more commonly in the pediatric population, and constitutes the most frequent CNS malignancy in children, accounting for approximately one-third of pediatric brain tumors[1-3]. Pilocytic astrocytoma (PA), previously referred to as polar spongioablastoma, cystic cerebellar astrocytoma, or juvenile PA (JPA), is a distinct histologic and biologic subset of LGG initially described by Harvey Cushing in 1931[4,5]. The term “pilocytic” has been used due to the microscopic appearance of cells with long, thin bipolar processes resembling hairs[5]. Rosenthal fibers may be typically found on hematoxylin and eosin staining as elongated eosinophilic bundles. PA comprises roughly 25%-30% and 2%-5% of all CNS tumors in children and adults, respectively[6,7]. These tumors are typically classified as World Health Organization (WHO) grade I tumors[8]. The majority of PAs usually portend favorable prognosis with low growth rates; however, a more aggressive clinical course may be observed in adult PAs and pilomyxoid astrocytomas[9,10]. PAs mostly arise in the cerebellum, chiasmatic, and hypothalamic areas; nevertheless, these tumors may also be seen at other locations including the cerebral hemispheres, brainstem, and spinal cord[11]. Surgery is the main modality of management for PA, and gross total resection is intended to achieve tumor eradication[12-14]. Observation has been considered given the relatively favorable prognosis to spare patients from adverse effects of adjuvant therapy; however, failure to achieve optimal surgical tumor removal may result in subsequent recurrences and the prognosis may be affected by age, disease localization, and extent of resection[15-19]. In this context, radiation therapy (RT) may be considered for the management of selected patients with PA. Irradiation has been shown to improve progression-free survival (PFS) for PA; nevertheless, there have been concerns over the utility of RT due to the risk of radiation-induced toxicity[19-25]. Since a significant proportion of patients with PA are children with vulnerability to adverse effects of irradiation, several strategies have been introduced such as reserving RT for salvage treatment for selected patients, decreasing the total delivered doses, and improving the toxicity profile of radiation delivery through focused stereotactic irradiation[23-25].

Herein, we provide a concise review of radiosurgery for the management of PA in light of the literature.

RADIOSURGERY FOR PA

PA comprises a considerable proportion of LGG particularly in the pediatric population. Typically, PAs are well circumscribed WHO grade I tumors with low growth rates and indolent disease course. PAs may present in the form of solid tumors or may include both cystic and solid components. While some patients may have no symptoms until the tumors grow to a substantial size before diagnosis, symptomatic presentation may occur depending on lesion location and association with critical neurovascular structures. The disease course may also be affected by patient age with adult PAs portending a typically poorer prognosis compared to JPA. Surgery is the principal therapy; however, the extent of resection is a critical factor and patients undergoing incomplete surgical removal of the
tumor may suffer from recurrences particularly within the first years of postoperative period\cite{26}. While there is no consensus on radiotherapeutic management, selected patients may benefit from irradiation particularly in the setting of inoperability, incomplete resection, or recurrent disease. Conventionally fractionated RT has been traditionally utilized for radiotherapeutic management. More recently, stereotactic irradiation strategies have been introduced for improving the toxicity profile of radiation delivery without jeopardizing disease control.

Radiosurgery in the forms of stereotactic radiosurgery (SRS), hypofractionated stereotactic RT (HFSRT), and Stereotactic Body RT (SBRT) has been judiciously used for management of several CNS disorders and tumors throughout the human body with promising therapeutic outcomes\cite{27-41}. Unique features of radiosurgical management include focused and precise targeting of well-defined tumors under stereotactic immobilization and image guidance. Also, radiosurgery typically offers a condensed treatment schedule, which may be particularly well suited for children with requirement of anesthesia during irradiation. While conventionally fractionated RT is delivered over 5 to 6 wk, overall treatment time is significantly reduced in radiosurgical management, which includes the delivery of a single or a few fractions in a significantly shorter overall treatment time. Since a substantial proportion of patients with PA are children, the requirement for daily anesthesia is a critical consideration and abbreviated treatment with radiosurgery may offer a viable radiotherapeutic approach. Multiple convergent beams are focused on the target to achieve excellent target coverage in radiosurgical applications. Steep dose gradients around the target allow for optimal normal tissue sparing, which may be of utmost importance for the management of children with PA to improve the toxicity profile of radiation delivery. The need for expanding the target with margins to account for setup uncertainties is eliminated or minimized under image guidance and robust stereotactic immobilization of the patients which may contribute to reduced normal tissue exposure in radiosurgery of PAs. Table 1 shows summarized data from selected series of stereotactic irradiation for management of PA in pediatric and adult patients.

Murphy et al\cite{42} assessed outcomes of Gamma Knife stereotactic radiosurgery (GKSRS) for PA. Median patient age was 14 years (range: 2-84 years) at the time of GKSRS. Median tumor volume was 3.45 cc (range: 0.17-33.7 cc). Median margin dose was 14 Gy (range: 4-22.5 Gy). At last follow-up, 5- and 10-year overall survival (OS) rates were 95.7% and 92.5%, respectively, whereas 5- and 10-year PFS rates were 74.0% and 69.7%, respectively. In this largest study of single-session GKSRS including 141 patients from 9 International Radiosurgery Research Foundation centers, the authors concluded that GKSRS provided favorable long-term PFS and OS\cite{42}.

Trifiletti et al\cite{43} from the University of Virginia evaluated GK-based stereotactic irradiation in a series of 28 patients with PA. Median age was 17.4 years (range: 2-70.3 years). Median tumor volume was 1.84 cc and the median margin dose was 16 Gy. One patient received multi-fraction SRS with a total dose of 15 Gy delivered in three fractions. Local tumor control rate was 93% without adverse radiation effects. Actuarial PFS rates at 1, 3, 6, and 12 years were 96%, 96%, 96%, and 80%, respectively. Authors concluded that favorable tumor control rates may be achieved by SRS as a viable technique for management of PA in the primary or recurrent disease setting\cite{43}.

Simonova et al\cite{44} assessed long-term outcomes with GK-based stereotactic irradiation for PA. Their series included 25 pediatric patients with a median age of 13 years (range: 3-17 years). Median target volume was 2.7 cc (range: 0.2-25 cc). The 10-year OS and PFS rates were 96% and 80%, respectively. Patients with a planning target volume of 2.7 cc or less had increased PFS. Authors concluded that radiosurgery offers an alternative treatment modality, providing long term local control for management of small residual or recurrent PAs\cite{44}.

Lizarraga et al\cite{45} evaluated linear accelerator based stereotactic irradiation for progressive residual PAs in a series of 12 patients. Median age at the start of stereotactic irradiation was 21 years (range: 5-41 years). There were no radiation-induced adverse effects in the follow-up period, and probabilities of long-term PFS and disease-specific survival were 73.3% and 91.7%, respectively\cite{45}.

Hallemeier et al\cite{46} assessed GKSRS for the management of recurrent or unresectable PA in a series of 18 patients treated at the Mayo Clinic. Median age at GKSRS was 23 years (range: 4-56 years). Median treatment volume for GKSRS was 9.1 cc. Median margin dose was 15 and 16 Gy for patients with and without prior RT, respectively. PFS rates were 65%, 41%, and 17% at 1, 5, and 10 years, respectively, at a median follow-up duration of 8 years. OS rates were 94%, 71%, and 71%, at 1, 5, and 10 years after GKSRS, respectively. The authors concluded that GKSRS may serve as a meaningful therapeutic option for management of recurrent or unresectable PAs in the setting of treatment failure with surgery and/or external beam RT considering the durable local tumor control and low permanent radiation induced morbidity with GKSRS\cite{46}.

Kano et al\cite{47} evaluated GKSRS for the management of newly diagnosed or recurrent JPAs in a series of 50 pediatric patients with a median age of 10.5 years (range: 4.2-17.9 years). Median margin dose was 14.5 Gy. PFS after GKSRS (including tumor growth and cyst enlargement) was 91.7%, 82.8% and 70.8% at 1, 3 and 5 years, respectively, for the entire series at a median follow-up duration of 55 mo. The authors concluded that response to treatment was better in small volume residual solid JPAs, and GKSRS should be considered when resection is not feasible or in the presence of early recurrence\cite{47}.
### Table 1 Selected series of stereotactic irradiation for management of pilocytic astrocytoma in pediatric and adult patients

| Ref.          | Publication year and study period | Histology | Number of patients | Age (yr)                       | Setting                                      | Treatment          | Tumor size                | Dose                        | Prior RT | Follow-up duration | PFS / tumor control |
|---------------|-----------------------------------|-----------|--------------------|--------------------------------|---------------------------------------------|-------------------|---------------------------|---------------------------|-----------|-------------------|------------------------|
| Murphy et al  | 2019 (1990-2016)                  | PA        | 141                | Median age 14 yr (range: 2-84 yr) | As part of initial management or salvage therapy | GKSRS             | Median 3.45 cc           | Median margin dose 16 Gy | 21 patients | Median 67.3 mo     | PFS 74.0% at 5 yr; PFS 69.7% at 10 yr |
| Trifiletti et al | 2017 (1990-2015)                | PA        | 28                 | Median age 17.4 yr (range: 2-70.3 yr) | As part of initial management or salvage therapy | GK-based SRS or SRT | Median 1.84 cc          | Median margin dose 16 Gy for single fraction SRS, and 15 Gy delivered in 3 fractions for SRT | 4 patients | Median 5.4 yr      | PFS 96% at 6 yr; Tumor control 93%       |
| Simonova et al | 2016 (1992-2002)                  | PA        | 25                 | Median age 13 yr (range: 3-17 yr)    | As part of initial management or salvage therapy | GK-based SRS or SRT | Median 2.7 cc           | Median margin dose 16 Gy for patients receiving single fraction, median dose 25 Gy delivered in 5 fractions for SRT | 2 patients | Median 15 yr       | PFS 80% at 10 yr            |
| Lizarraga et al | 2012 (1995-2010)                | PA        | 12                 | Median age 21 yr (range: 5-41 yr)     | Salvage therapy                              | LINAC-based SRS or SRT | Median 6.5 cc for SRT; Median 1.69 cc for SRS | Median dose 18.75 Gy for SRS and median dose 50.4 Gy delivered in 28 fractions for SRT | 0 patients | Median 37.5 mo     | PFS 73.3% at long term               |
| Hallemeier et al | 2012 (1992-2005)                | PA        | 18                 | Median age 23 yr (range: 4-56 yr)     | As part of initial management or salvage therapy | GKSRS             | Median 9.1 cc           | Median margin dose 15 Gy | 10 patients | Median 8 yr        | PFS 41% at 5 yr; Tumor control 75%       |
| Kano et al[47] | 2009 (1987-2006)                  | PA        | 50                 | Median age 10.5 yr (range: 4.2-17.9 yr) | As part of initial management or salvage therapy | GKSRS             | Median 2.1 cc           | Median margin dose 14.5 Gy | 5 patients | Median 55.5 mo     | PFS 70.8% at 5 yr            |
| Kano et al[48] | 2009 (1994-2006)                  | PA        | 14                 | Median age 12 yr (range: 19-52 yr)    | As part of initial management or salvage therapy | GKSRS             | Median 4.7 cc           | Median margin dose 13.3 Gy | 6 patients | Median 36.3 mo     | PFS 31.5% at 5 yr            |
| Hadjipanayis et al[49] | 2002(1987-2000)              | PA        | 37                 | Median age 14 yr (range: 3-52 yr)     | As part of initial management or salvage therapy | GKSRS             | Median 3 cc            | Median margin dose 15 Gy | 9 patients | Median 28 mo after GKSRS | Tumor control 68% |
| Borthius et al[50] | 2002 (1978-1997)                   | PA        | 19                 | Mean age 10.6 yr (range: 2-60 yr)     | Adjuvant therapy                              | GKSRS             | Median 2.2 cc           | Median margin dose 10 Gy | 2 patients | Median radiological follow-up 4.7 yr | Tumor control 94.7% |
| Somaza et al[51] | 1996 (1990-1993)                 | PA        | 9                  | Mean age 8.6 yr (range: 4-17 yr)      | Adjuvant or salvage therapy                  | GKSRS             | Mean tumor diameter 16 mm | Median margin dose 15 Gy | 2 patients | Median 19 mo       | Tumor control 100%       |

GKSRS: Gamma Knife stereotactic radiosurgery; LINAC: Linear accelerator; PA: Pilocytic astrocytoma; PFS: Progression-free survival; SRS: Stereotactic radiosurgery; SRT: Stereotactic radiation therapy.

In another study, Kano et al[48] separately assessed GKSRS for the management of PA in adult patients. A total of 14 patients treated using GKSRS between 1994 and 2006 were included. Median age was 32 years (range: 19-52 years). Median margin dose was 13.3 Gy, and median radiosurgery target volume was 4.7 cc. At a median follow-up duration of 36.3 mo, 3 patients died and 11 patients were...
alive with OS rates of 100%, 88.9%, and 88.9% at 1, 3, and 5 years, respectively, for the entire series. The authors emphasized that PA could behave more aggressively in adult patients, and thus additional treatment strategies could be considered for unresectable PAs located in critical brain areas. The authors concluded that GKSRS was most valuable for patients after maximal feasible surgical resection and delayed cyst progression contributed to late loss of tumor control\[48\].

Hadjipanayis et al\[49\] performed a retrospective analysis of 37 patients receiving GKSRS at the University of Pittsburgh Medical Center for recurrent or critically located PAs. Median age at GKSRS was 14 years. At a median follow-up duration of 28 mo after GKSRS and 59 mo after diagnosis, 33 (89%) of 37 patients were alive, providing a 7-year actuarial survival rate of 76%. Follow-up imaging revealed tumor control in 25 (68%) of 37 patients. While 10 patients had complete resolution of tumor, 8 had greater than 50% reduction in tumor volume. There were no procedure-related permanent morbidity or mortality. The authors concluded that GKSRS could be used as part of multimodal management for progressive, recurrent, or unresectable PAs and GKSRS could replace fractionated RT and chemotherapy in selected patients as a safe and promising treatment modality\[49\].

Boethius et al\[50\] evaluated outcomes of 19 patients receiving GKSRS for PA. Mean age was 10.6 years, and the study group included 16 pediatric patients. Median tumor volume was 2.2 cc. A median marginal dose of 10 Gy was used given that majority of tumors were localized within or in close neighborhood of the brainstem. A satisfactory tumor control rate of 94.7% was achieved at a median radiological follow-up duration of 4.7 years and median clinical follow-up duration of 7 years albeit with a relatively lower GKSRS dose\[50\].

Somaza et al\[51\] from Pittsburgh University assessed the utility of GKSRS in adjuvant treatment of 9 pediatric patients with growing and unresectable deeply seated PAs. Mean margin dose was 15 Gy. At a mean follow-up duration of 19 mo, tumor control was achieved in all patients with significant tumor shrinkage in 5 patients and no further growth in 4 patients. No patients had early or late toxicity. The authors concluded that GKSRS served as a safe and effective therapeutic modality for management of deeply seated and small volume PAs\[51\].

Overall, stereotactic irradiation has been utilized for management of PA in both children and adults as a promising treatment modality. Since adverse effects of irradiation constitute major concerns over the use of RT for treatment of PAs, improving the toxicity profile of radiation delivery is a critical aspect of contemporary patient management in the millennium era. Within this context, focused and precise targeting of well circumscribed PAs under stereotactic immobilization and image guidance may offer great potential for achieving an improved therapeutic ratio by virtue of radiosurgical techniques. Another advantage of radiosurgery may be the completion of therapy in a usually shorter overall treatment time, which may be particularly well suited for children with requirement of anesthesia during irradiation. Although radiosurgery is a relatively newer treatment paradigm compared to conventional RT, it has gained widespread popularity and adoption with growing body of evidence supporting its utility. Nevertheless, there is still room for further improvements with the need for high level of evidence to reach multidisciplinary consensus for optimal management of PAs.

**CONCLUSION**

PA may be seen in both adults and children as a distinct histologic and biologic subset of LGG. Surgery is the principal treatment for management of PAs, however, selected patients may benefit from irradiation particularly in the setting of inoperability, incomplete resection, or recurrent disease. While conventionally fractionated RT has been traditionally utilized for radiotherapeutic management, stereotactic irradiation strategies have been introduced more recently to improve the toxicity profile of radiation delivery without compromising tumor control. PAs may be suitable for radiosurgical management due to their typical appearance as well circumscribed lesions. Focused and precise targeting of these well-defined lesions under stereotactic immobilization and image guidance may offer great potential for achieving an improved therapeutic ratio by virtue of radiosurgical techniques. Given the high conformity along with steep dose gradients around the target volume allowing for reduced normal tissue exposure, radiosurgery may be considered as a viable modality of radiotherapeutic management. Another advantage of radiosurgery may be the completion of therapy in a usually shorter overall treatment time, which may be particularly well suited for children with requirement of anesthesia during irradiation.

Although radiosurgery has a shorter history compared to conventional RT, there is accumulating data on its utility for management of several tumors throughout the human body. In the context of PAs, several studies have addressed its use particularly as an adjuvant or salvage treatment modality. Nevertheless, despite the growing body of evidence supporting the utility of radiosurgery, there is need for high level of evidence to dictate treatment decisions and establish its optimal role in management of PA. We believe that both SRS and SRT may be considered as viable radiosurgical methods for management of PA and selection between SRS and SRT should be based on patient, tumor, and treatment characteristics.
In the context of future perspectives, immunotherapy, identification of driver alterations and introduction of efficacious targeted therapies may pave the way for contemporary treatment approaches for PAs. Further extensive investigation is warranted to develop safe and effective treatment strategies for management of PAs.

FOOTNOTES

Author contributions: Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, Gumustepe E, Ozcan F, Colak O, Gursoy AT, Dursun CU, Tugcu AO, Dogru GD, and Arslan R played significant roles in data acquisition, interpretation of data, and reviewing and writing of the manuscript; Elcim Y, Gundem E, and Dirican B revised the manuscript for important intellectual content; Beyzadeoglu M took part in designing, reviewing, and writing the manuscript and revising the manuscript for important intellectual content; All authors have read and approved the final manuscript.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Turkey

ORCID number: 
Omer Sager 0000-0001-7866-2598; Ferrat Dincoglan 0000-0002-7686-0976; Selcuk Demiral 0000-0002-3408-0323; Bora Uysal 0000-0002-7288-7005; Hakan Gamsiz 0000-0002-7791-3487; Esra Gumustepe 0000-0002-3664-4663; Fatih Ozcan 0000-0002-1965-7067; Onurhan Colak 0000-0003-1421-4678; Ahmet Tarik Gursoy 0000-0002-9404-4578; Cemal Ugur Dursun 0000-0001-6095-3506; Ahmet Oguz Tugcu 0000-0001-6229-9405; Galip Dogukan Dogru 0000-0002-4906-8087; Rukiyye Arslan 0000-0003-2835-5893; Yelda Elcim 0000-0001-6274-1267; Esin Gundem 0000-0002-9482-8567; Bahar Dirican 0000-0002-1749-5375; Murat Beyzadeoglu 0000-0003-1035-7209.

S-Editor: Ma YJ
L-Editor: Filipodia
P-Editor: Ma YJ

REFERENCES

1 Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg 2011; 115: 948-965 [PMID: 22043865 DOI: 10.3171/2011.7.JNS101238]
2 Chalil A, Ramaswamy V. Low Grade Gliomas in Children. J Child Neurol 2016; 31: 517-522 [PMID: 26286938 DOI: 10.1177/0883073815599259]
3 de Blank P, Bandopadhyay P, Haas-Kogan D, Foula L, Fungasaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr 2019; 31: 21-27 [PMID: 30531227 DOI: 10.1097/MOP.0000000000001717]
4 Koeller KK, Rushing EJ. From the archives of the AFIP: pilocytic astrocytoma: radiologic-pathologic correlation. Radiographics 2004; 24: 1693-1708 [PMID: 15537977 DOI: 10.1148/rg.24604146]
5 Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015; 129: 775-788 [PMID: 25792358 DOI: 10.1007/s00401-014-1410-7]
6 Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendrogial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489 [PMID: 15977639 DOI: 10.1093/jnen/64.6.479]
7 Lee KJ, Marchan E, Peterson J, Harrell AC, Quinones-Hinojosa A, Brown PD, Trifiletti DM. Management and Survival of Adult Patients with Pilocytic Astrocytoma in the National Cancer Database. World Neurosurg 2018; 112: e881-e887 [PMID: 29427814 DOI: 10.1016/j.wneu.2018.01.208]
8 Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803-820 [PMID: 27157931 DOI: 10.1007/s00401-016-1545-1]
9 Ryu IH, Jung TY, Lee GI, Lee KH, Jung SH, Jung S, Baek HJ. Differences in the clinical courses of pediatric and adult pilocytic astrocytomas with progression: a single-institution study. Childs Nerv Syst 2015; 31: 2063-2069 [PMID: 26293677 DOI: 10.1007/s00381-015-2887-2]
10 Kulac I, Tihan T. Pilomyxoid astrocytomas: a short review. Brain Tumor Pathol 2019; 36: 52-55 [PMID: 30945015 DOI: 10.1007/s10144-019-00343-0]
11 Sadighi Z, Slopis J. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity. J Child Neurol 2013; 28: 625-632 [PMID: 23439714 DOI: 10.1177/0883073813476141]
12 Kayama T, Tominaga T, Yoshimoto T. Management of pilocytic astrocytoma. Neurosurg Rev 1996; 19: 217-220 [PMID: 9007882 DOI: 10.1007/BF0034833]
13 Dirven CM, Mooij JJ, Molenaar WM. Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature. Childs Nerv Syst 1997; 13: 17-23 [PMID: 9083697 DOI: 10.1007/s003810050033]
Sager O et al. Radiosurgery for pilocytic astrocytomas

322-327 [PMID: 23374003 DOI: 10.4149/neo_2013_043]

38 Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, Colak O, Ozcak F, Gundem E, Elcim Y, Dirican B, Beyzadeoglu M. Concise review of stereotactic irradiation for pediatric glial neoplasms: Current concepts and future directions. World J Methodol 2021; 11: 61-74 [PMID: 34026579 DOI: 10.5662/wjm.v11i3.61]

39 Demiral S, Dincoglan F, Sager O, Gamsiz H, Uysal B, Gundem E, Elcim Y, Dirican B, Beyzadeoglu M. Hypofractionated stereotactic radiotherapy (HFSRT) for WHO grade I anterior clinoid meningiomas (ACM). Jpn J Radiol 2016; 34: 730-737 [PMID: 27659448 DOI: 10.1007/s11604-016-0581-z]

40 Dincoglan F, Sager O, Uysal B, Demiral S, Gamsiz H, Gundem E, Elcim Y, Dirican B, Beyzadeoglu M. Evaluation of hypofractionated stereotactic radiotherapy (HFSRT) to the resection cavity after surgical resection of brain metastases: A single center experience. Indian J Cancer 2019; 56: 202-206 [PMID: 31383364 DOI: 10.3171/2019.9.IJC_345_18]

41 Dincoglan F, Sager O, Uysal B, Onal E, Ekmen A, Dirican B, Beyzadeoglu M. Fractionated stereotactic radiosurgery for locally recurrent brain metastases after failed stereotactic radiosurgery. Indian J Cancer 2019; 56: 151-156 [PMID: 31062775 DOI: 10.4103/ijc.IJC_786_18]

42 Murphy ES, Parsai S, Kano H, Sheehan JP, Martinez-Alvarez R, Martinez-Moreno N, Kondziolka D, Simonova G, Liscak R, Mathieu D, Lee CC, Yang HC, Lee JY, McShane BJ, Fang F, Trifiletti DM, Sharma M, Barnett GH. Outcomes of stereotactic radiosurgery for pilocytic astrocytoma: an international multiinstitutional study. J Neurosurg 2019; 1-9 [PMID: 31783364 DOI: 10.3171/2019.9.JNS191335]

43 Trifiletti DM, Peach MS, Xu Z, Kersh R, Showalter TN, Sheehan JP. Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma. J Neurooncol 2017; 134: 297-302 [PMID: 28567590 DOI: 10.1007/s11060-017-2521-x]

44 Simonova G, Kozubikova P, Liscak R, Novotny J Jr. Leksell Gamma Knife treatment for pilocytic astrocytomas: long-term results. J Neurosurg Pediatr 2016; 18: 58-64 [PMID: 26991883 DOI: 10.3171/2015.10.PEDS14443]

45 Lizarraga KJ, Gorgulho A, Lee SP, Rauscher G, Selch MT, DeSalles AA. Stereotactic radiation therapy for progressive residual pilocytic astrocytomas. J Neurosurg 2012; 109: 129-135 [PMID: 22644536 DOI: 10.3171/jns.2012.109.01.0014]

46 Hallemeier CL, Pollock BE, Schomberg PJ, Link MJ, Brown PD, Stafford SL. Stereotactic radiosurgery for recurrent or unresectable pilocytic astrocytoma. Int J Radiat Oncol Biol Phys 2012; 83: 107-112 [PMID: 22019245 DOI: 10.1016/j.ijrobp.2011.05.038]

47 Kano H, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for pilocytic astrocytomas part 1: outcomes in adult patients. J Neurosurg 2009; 95: 211-218 [PMID: 19468691 DOI: 10.1007/s11060-009-9913-5]

48 Kano H, Niranjan A, Kondziolka D, Flickinger JC, Pollack IF, Jakacki RI, Lunsford LD. Stereotactic radiosurgery for pilocytic astrocytomas part 2: outcomes in pediatric patients. J Neurosurg 2009; 95: 219-229 [PMID: 19468692 DOI: 10.1007/s11060-009-9912-6]

49 Hadjipanayis CG, Kondziolka D, Gardner P, Niranjan A, Dagam S, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary. J Neurosurg 2002; 97: 56-64 [PMID: 12134933 DOI: 10.3171/jns.2002.97.1.0056]

50 Boëthius J, Ulfarsson E, Rahn T, Lippitz B. Gamma knife radiosurgery for pilocytic astrocytomas. J Neurosurg 2002; 97: 677-680 [PMID: 12507119 DOI: 10.3171/jns.2002.97.supplement]

51 Somaza SC, Kondziolka D, Lunsford LD, Flickinger JC, Bissonette DJ, Albright AL. Early outcomes after stereotactic radiosurgery for growing pilocytic astrocytomas. Pediatr Neurosurg 1996; 25: 109-115 [PMID: 9144708 DOI: 10.1159/000121107]
